Theralase Technologies Inc (OP:TLTFF)

0.1313 +0.0059 (+4.70%)

Delayed Quote Updated: 11:48 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Theralase Technologies Inc

< Previous 1 2 3 4 Next >

Theralase(R) Closes Non-Brokered Private Placement

June 17, 2025

Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase Completes Annual General and Special Meeting

June 12, 2025

Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Theralase Annual General Meeting

June 05, 2025

Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) 1Q2025 Financial Statements

May 30, 2025

Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes

February 13, 2025

Via ACCESS Newswire

Theralase(R) Launches New Clinical Study Site in Canada

December 05, 2024

Via ACCESSWIRE

CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025

May 29, 2025

This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025)...

Via Newsfile

Theralase to Present Groundbreaking Research at ASTRO 2025

May 28, 2025

Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase Provides Corporate Update

May 20, 2025

Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association

May 05, 2025

Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase Discovers New Mechanism of Action of Lead Drug

April 28, 2025

Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Closes Non-Brokered Private Placement

April 14, 2025

Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments

April 10, 2025

Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Ruvidar Demonstrates 7 Year Complete Response

April 07, 2025

Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical...

Via Newsfile

Ruvidar Effective in the Treatment of Herpes

March 24, 2025

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Releases 2024 Annual Financial Statements

March 12, 2025

Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Closes Non-Brokered Private Placement

March 11, 2025

Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

March 10, 2025

Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

February 25, 2025

Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Topics Death

Theralase(R) Demonstrates Effective Treatment of Herpes

February 12, 2025

Via ACCESS Newswire

Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

February 10, 2025

Via ACCESS Newswire

Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

January 27, 2025

Via ACCESS Newswire

Theralase(R) Launches Three New Clinical Study Sites in USA

December 09, 2024

Via ACCESSWIRE

Theralase(R) Release’s 3Q2024 Financial Statements

November 27, 2024

Via ACCESSWIRE

Theralase(R) Closes Non-Brokered Private Placement

November 15, 2024

Via ACCESSWIRE

Theralase(R) Extends Warrants

November 12, 2024

Via ACCESSWIRE

Theralase(R) Provides Update on Bladder Cancer Clinical Study

October 07, 2024

Via ACCESSWIRE

Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

September 24, 2024

Via ACCESSWIRE

Theralase(R) Extends Warrants

September 19, 2024

Via ACCESSWIRE

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

September 03, 2024

Via ACCESSWIRE

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.